论文部分内容阅读
目的:观察康复新液联合兰索拉唑片治疗糜烂性胃炎的临床疗效。方法:纳入107例糜烂性胃炎患者,按照随机数字表法随机分为治疗组54例与对照组53例。对照组给予兰索拉唑片治疗,治疗组在对照组基础上结合康复新液治疗。2组疗程均为4周。观察2组的疗效,治疗前后胃镜积分、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C-反应蛋白(CRP)]水平的变化以及用药期间不良反应发生情况。结果:治疗组总有效率(88.89%)高于对照组(71.70%),差异有统计学意义(P<0.05)。治疗后,2组胃镜积分与TNF-α、IL-6、CRP水平均较治疗前降低(P<0.05);治疗组胃镜积分与TNF-α、IL-6、CRP水平均低于对照组(P<0.05)。2组患者均未见严重不良反应发生。结论:康复新液联合兰索拉唑片治疗糜烂性胃炎患者疗效显著,作用机制可能与降低血清TNF-α、IL-6、CRP水平相关,且较为安全可靠。
Objective: To observe the clinical effect of Kangfuxin solution combined with lansoprazole tablets in the treatment of erosive gastritis. Methods: A total of 107 patients with erosive gastritis were enrolled and randomly divided into treatment group (n = 54) and control group (n = 53) according to the random number table method. The control group was treated with lansoprazole tablets, and the treatment group was treated with Kangfuxinye on the basis of the control group. The two courses of treatment were 4 weeks. The curative effect of the two groups were observed, the gastroscope score before and after treatment, the changes of inflammatory cytokines (TNF-α, IL-6 and C-reactive protein) Adverse reactions occurred. Results: The total effective rate (88.89%) in the treatment group was higher than that in the control group (71.70%), the difference was statistically significant (P <0.05). After treatment, the scores of gastroscope integral and the levels of TNF-α, IL-6 and CRP in the two groups were lower than those before treatment (P <0.05); the scores of gastroscope and the levels of TNF-α, IL-6 and CRP in the treatment group were lower than those in the control group P <0.05). No serious adverse reactions occurred in 2 groups of patients. CONCLUSION: Kangfuxin solution combined with lansoprazole tablets has significant therapeutic effect on patients with erosive gastritis. The mechanism may be related to the reduction of serum TNF-α, IL-6 and CRP levels, and is safe and reliable.